Key Takeaways Weight-loss surgery procedures are decliningThere was a more than 20% drop in surgeries in recent yearsGLP-1 ...

Companies have “tremendous concern” about the financial viability of these medications, the president and CEO of the Business ...

U.S. bariatric surgeries fell below 200,000 in 2024, marking a more than 20% decline from the prior year, new data show. Research linked the surgery to greater lifetime cardiovascular risk reduction ...

Originally developed for Type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the weight-loss medication market. And in recent years, their popularity has soared due to ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

USDA data shows snack units sold remain stable through 2024, even as prescription rates for GLP-1 drugs climb, suggesting opportunity – and caution – for snack manufacturers targeting shifting ...

North Carolina Poison Control is warning GLP-1 drug users to use caution when taking the medication. Poison control said last year it averaged one to two calls a day about GLP-1 drugs with 80 percent ...

The GLP-1 revolution shows no signs of slowing down. A pill version of the appetite-suppressing drug, Wegovy, hit the shelves of 70,000 U.S. pharmacies in January 2026. In the same month, UK-based ...

GLP-1 medications offer cancer survivors a tool to manage treatment-related weight gain through coordinated care. If you've finished cancer treatment and found yourself struggling with weight changes ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...